Clinical Trial: A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants

U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07559240) titled 'A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants' on April 23.

Brief Summary: The purpose of this study is to evaluate the pharmacokinetic profile and safety of a single subcutaneous injection of HDM1005 solution in participants with impaired kidney function compared to healthy participants.

Study Start Date: May 15

Study Type: INTERVENTIONAL

Condition: Overweight Obese

Intervention: DRUG: HDM1005

2.0 mg, SC, single dose

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Disclaimer: Curated by HT Syndication....